These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 27872957)
21. The Application of 18 F-FES PET in Clinical Cancer Care : A Systematic Review. Huang YT; Chen TW; Chen LY; Huang YY; Lu YS Clin Nucl Med; 2023 Sep; 48(9):785-795. PubMed ID: 37482660 [TBL] [Abstract][Full Text] [Related]
22. Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer. van Kruchten M; de Vries EG; Glaudemans AW; van Lanschot MC; van Faassen M; Kema IP; Brown M; Schröder CP; de Vries EF; Hospers GA Cancer Discov; 2015 Jan; 5(1):72-81. PubMed ID: 25380844 [TBL] [Abstract][Full Text] [Related]
23. [18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant. Iqbal R; Yaqub M; Bektas HO; Oprea-Lager DE; de Vries EGE; Glaudemans AWJM; Aftimos P; Gebhart G; Beelen AP; Schuit RC; Windhorst AD; Boellaard R; Menke-van der Houven van Oordt CW Clin Cancer Res; 2023 Jun; 29(11):2075-2084. PubMed ID: 36735488 [TBL] [Abstract][Full Text] [Related]
24. Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating Kumar M; Salem K; Jeffery JJ; Yan Y; Mahajan AM; Fowler AM J Nucl Med; 2021 Apr; 62(4):500-506. PubMed ID: 32859700 [TBL] [Abstract][Full Text] [Related]
25. Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader. Heidari P; Deng F; Esfahani SA; Leece AK; Shoup TM; Vasdev N; Mahmood U Clin Cancer Res; 2015 Mar; 21(6):1340-7. PubMed ID: 25609068 [TBL] [Abstract][Full Text] [Related]
26. Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer Paquette M; Lavallée É; Phoenix S; Ouellet R; Senta H; van Lier JE; Guérin B; Lecomte R; Turcotte ÉE J Nucl Med; 2018 Feb; 59(2):197-203. PubMed ID: 28798032 [TBL] [Abstract][Full Text] [Related]
27. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Dehdashti F; Mortimer JE; Trinkaus K; Naughton MJ; Ellis M; Katzenellenbogen JA; Welch MJ; Siegel BA Breast Cancer Res Treat; 2009 Feb; 113(3):509-17. PubMed ID: 18327670 [TBL] [Abstract][Full Text] [Related]
29. Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside. Jayaraman S; Reid JM; Hawse JR; Goetz MP Endocrinology; 2021 Dec; 162(12):. PubMed ID: 34480554 [TBL] [Abstract][Full Text] [Related]
30. [18F]-fluoroestradiol quantitative PET imaging to differentiate ER+ and ERα-knockdown breast tumors in mice. Paquette M; Ouellet R; Archambault M; Croteau É; Lecomte R; Bénard F Nucl Med Biol; 2012 Jan; 39(1):57-64. PubMed ID: 22079037 [TBL] [Abstract][Full Text] [Related]
36. Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer. Peterson LM; Kurland BF; Link JM; Schubert EK; Stekhova S; Linden HM; Mankoff DA Nucl Med Biol; 2011 Oct; 38(7):969-78. PubMed ID: 21982568 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of tumour heterogeneity by Liu C; Hu S; Xu X; Zhang Y; Wang B; Song S; Yang Z Breast Cancer Res; 2022 Aug; 24(1):57. PubMed ID: 36028895 [TBL] [Abstract][Full Text] [Related]
38. The preliminary study of 16α-[18F]fluoroestradiol PET/CT in assisting the individualized treatment decisions of breast cancer patients. Sun Y; Yang Z; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y PLoS One; 2015; 10(1):e0116341. PubMed ID: 25617853 [TBL] [Abstract][Full Text] [Related]
39. Can Gupta M; Datta A; Choudhury PS; Dsouza M; Batra U; Mishra A World J Nucl Med; 2017; 16(2):133-139. PubMed ID: 28553180 [TBL] [Abstract][Full Text] [Related]
40. 18F-Fluoroestradiol PET/CT Correctly Diagnosed 18F-FDG-Avid Inflammatory Lymph Nodes in a Patient With Estrogen Receptor-Positive Breast Cancer. Yamane T; Ueda S; Seto A; Kuji I Clin Nucl Med; 2018 May; 43(5):379-380. PubMed ID: 29485433 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]